Savitzky had joined Lonza in March 2015 as Head of Finance & Controlling for the pharma and biotech segment
Lonza has appointed Rodolfo Savitzky as its new Chief Financial Officer. In this function he will be succeeding Toralf Haag, who after 11 years of service for Lonza accepted an offer from the Voith Group in Germany to become their new CFO and member of the Corporate Board of Management. The change will be effective as of October 1, 2016, when Rodolfo Savitzky will also succeed Toralf Haag as a member of the Lonza Executive Committee.
Rodolfo Savitzky (54) joined Lonza in March 2015 as Head of Finance & Controlling for the pharma and biotech segment. Previously, he was Chief Financial Officer for the Animal Health Division of Novartis. Prior to this position, Rodolfo Savitzky held various financial management positions with increasing responsibilities at Novartis and Procter & Gamble. He holds an MBA in Finance/Economics from the University of Chicago. With his broad financial and industry background, his thorough understanding of Lonza’s strategic direction and his contributions to the pharma and biotech segment, Rodolfo Savitzky brings the necessary skillset to his new position.